News about Drug Discovery & Development

Nxera Pharma and Shionogi Launch QUVIVIQ in Japan

QUVIVIQ™ is an oral Dual Orexin Receptor Antagonist (DORA) for the treatment of insomnia that selectively binds to receptors of the wake-promoting neuropeptide orexin (OX1R and OX2R), inhibiting excessive wakefulness and facilitating the transition to sleep.

Drug Discovery & Development | 19/12/2024 | By Aishwarya |  426

Glenmark Introduces Lacosamide Oral Solution

Glenmark’s Lacosamide Oral Solution, 10 mg/mL is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat Oral Solution, 10 mg/mL of UCB, Inc.

Drug Discovery & Development | 16/12/2024 | By Aishwarya |  476

Valisure Partners with Picket Pharmaceuticals for Independent Certification of Injectable Drugs

Valisure and Picket Pharmaceuticals discovered their shared mission through their involvement in the End Drug Shortages Alliance (EDSA).

Drug Discovery & Development | 07/12/2024 | By Aishwarya |  224

Alembic Pharma Gets Tentative Approval for Olopatadine Hydrochloride Ophthalmic Solution

Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7 percent (OTC) has an estimated market size of USD 22 million for twelve months.

Drug Discovery & Development | 07/12/2024 | By Aishwarya |  480

Eugia Pharma Gets FDA Approval for Pazopanib Tablets

Aurobindo Pharma has announced that its wholly owned subsidiary company, Eugia Pharma Specialities, has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Pazopanib Tablets, 200 mg.

Drug Discovery & Development | 06/12/2024 | By Aishwarya |  367

KBI Biopharma Signs Manufacturing Contract with Alanis Therapeutics

As part of this collaborative agreement, KBI will oversee cell line development, process optimization, analytical and formulation development, and the manufacturing of Alanis’ pre-clinical antagonistic antibody (mAb).

Drug Discovery & Development | 04/12/2024 | By Aishwarya |  425

Lupin Gets Tentative Approval from FDA for Sitagliptin and Metformin Hydrochloride Tablets

Sitagliptin and Metformin Hydrochloride Tablets, 50 mg/500 mg and 50 mg/1000 mg are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Drug Discovery & Development | 02/12/2024 | By Aishwarya |  781

VectorBuilder Signs Deal with Sartorius to Advance Biopharmaceutical Innovation

The collaboration will focus on gene vector and mRNA bioprocess solutions and services, accelerating the development and clinical translation of innovative biopharmaceutical projects.

Drug Discovery & Development | 29/11/2024 | By Aishwarya |  342

Glenmark Rolls Out Travoprost Ophthalmic Solution

Glenmark’s Travoprost Ophthalmic Solution USP, 0.004 percent is bioequivalent and therapeutically equivalent to the reference listed drug, Travatan Z Ophthalmic Solution USP, 0.004 percent of Sandoz, Inc.

Drug Discovery & Development | 27/11/2024 | By Aishwarya |  410

Boehringer Ingelheim Unveils VETMEDIN Solution

VETMEDIN Solution, now available in the US, provides the same dual mode of action as VETMEDIN® Chewable Tablets.

Drug Discovery & Development | 25/11/2024 | By Aishwarya |  471